Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Connective tissue diseases

Treatment of digital ulcers in systemic sclerosis

Nature Reviews Rheumatology volume 7, pages 5–6 (2011)Cite this article

Subjects

Digital ulcers in patients with systemic sclerosis (SSc) can cause considerable disability; however, clinical trials addressing the treatment and prevention of digital ulcers in SSc are rare. A study has evaluated the potential benefit of the endothelin receptor antagonist bosentan in the treatment of SSc-related digital ulcers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hachulla, E. et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J. Rheumatol. 34, 2423–2430 (2007).

    PubMed  Google Scholar 

  2. Walker, U. A. et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann. Rheum. Dis. 66, 754–763 (2007).

    Article  CAS  Google Scholar 

  3. Galluccio, F. & Matucci-Cerinic, M. Registry evaluation of digital ulcers in systemic sclerosis. Int. J. Rheumatol. doi:10.1155/2010/363679.

  4. Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis. doi:10.1136/ard.2010.130658.

  5. Abraham, D. & Dashwood, M. Endothelin—role in vascular disease. Rheumatology (Oxford) 47 (Suppl. 5), v23–v24 (2008).

    Article  CAS  Google Scholar 

  6. Rademaker, M. et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298, 561–564 (1989).

    Article  CAS  Google Scholar 

  7. Scorza, R. et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin. Exp. Rheumatol. 19, 503–508 (2001).

    CAS  Google Scholar 

  8. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620–628 (2009).

    Article  CAS  Google Scholar 

  9. Humbert, M. & Cabane, J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelia receptor antagonist bosentan. Rheumatology (Oxford) 42, 191–193 (2003).

    Article  CAS  Google Scholar 

  10. Korn, J. H. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelia receptor antagonist. Arthritis Rheum. 50, 3985–3993 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Propedeutics of Internal Medicine, Clinic of Rheumatology, Medical University, Blvd Vasil Aprilov 15A, Plovdiv, 4002, Bulgaria

    Sevdalina Lambova

  2. Department for Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff Clinic, Benekestrasse 2–8, D-61231, Bad Nauheim, Germany

    Ulf Müller-Ladner

Authors
  1. Sevdalina Lambova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulf Müller-Ladner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulf Müller-Ladner.

Ethics declarations

Competing interests

S. Lambova receives grant/research support from the European League Against Rheumatism. U. Müller-Ladner is a consultant and on the speaker's bureau for Actelion, GlaxoSmithKline and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lambova, S., Müller-Ladner, U. Treatment of digital ulcers in systemic sclerosis. Nat Rev Rheumatol 7, 5–6 (2011). https://doi.org/10.1038/nrrheum.2010.207

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2010.207

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing